DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Information source: Melbourne Health
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Deep Vein Thrombosis

Intervention: Clexane (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Melbourne Health

Official(s) and/or principal investigator(s):
Paul Sparks, MBBS, PhD. FRACP, Principal Investigator, Affiliation: Melbourne Health

Summary

The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA). People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat their condition. Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies require the puncture of the leg veins . Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg. It is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs

Clinical Details

Official title: The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Incidence of deep vein thrombosis

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on

patient history or ECG evidence. Exclusion Criteria:

- Patients with a past history of DVT or PE.

- Patients with a history of clotting disorders

- Patients with active malignancies

- Patients requiring full heparinisation during and after the procedure.

- Chronic atrial flutter and atrial fibrillation ablation

Locations and Contacts

Royal Melbourne hospital, Melbourne, Victoria 3050, Australia
Additional Information

Starting date: August 2005
Last updated: May 28, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017